As managed care pharmacy navigates rapid transformations in policies, high-cost drug strategies, and innovative therapies, ...

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...

A new Commonwealth Fund report estimates that states' collective gross domestic products would shrink by $95 billion, with ...

Best practices can help MA plans improve their Star Ratings performance while allow for strategies for medication adherence ...

The Trump administration has expressed interest in eliminating or changing the Division of HIV Prevention in the CDC, which ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

One study found that Black women were 3 times more likely to die of maternal deaths due to cardiovascular disease than White ...

Ajai Chari, MD, stresses the importance of making bispecific therapies more accessible at the community level to improve outcomes in multiple myeloma.

One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

The American Society of Hematology (ASH) was already looking to expand its Bridge Grant program when changes to the National ...